undamentalytics Newsletter
Sign in

Biorestorative Therapies, Inc. income statement

In fiscal 2025, Biorestorative Therapies, Inc. reported revenue of $359,700, down 10.3% on the year before, operating income of −$15.6m (a -4350.1% margin) and net income of −$14.2m, or −$1.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Revenue0000100000000000
Cost of revenue—————————————000
Gross profit0000000—————0000
Research and development01212322211447109
General and administrative1322434452261611565
Operating income−4−6−5−5−7−8−8−8−8−3−26−19−15−12−16−14
Interest expense0100000—————————
Net interest income——————————−20110—
Income before tax——−6−6−8−9−9——————−9−14—
Income tax——000———————————
Net income−4−7−6−6−8−9−9−13−15−11−44−13−10−9−14−11
Diluted EPS−$0.21−$0.01−$0.01−$0.09−$0.13−$0.09−$0.07−$0.07−$0.08−$3.60−$14.09−$3.65−$2.47−$1.16−$1.58−$0.98
Diluted shares (average)27m32m39m61m59m98m129m182m177m3m3m4m4m8m9m11m
EBITDA−3−5−5−5−7−8−8−7−8−3−26−19−15−11−15−14

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BRTX vs CRVOBRTX vs CRDFBRTX vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biorestorative Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biorestorative Therapies, Inc.